Clinical evidence from multiple randomized controlled trials has established that completing a standard 5-year course of adjuvant endocrine therapy in hormone receptor-positive early breast cancer (HR [+] EBC) patients is associated with significant Survival Benefit and durable Protection [20]. The gene discussed is NR4A1; the disease is breast carcinoma.